← Leaderboards
Chien Hsing K. Chang
Immunomedics, Inc.
$1,347,339
Attributed
$1,347,339
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $520.8K · FY2006–11$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$1,347,339 · 4
By mechanism
R44$887,626 · 1
R43$268,570 · 2
R41$191,143 · 1
Top collaborators
No co-investigators on record.
Most similar at Immunomedics, Inc.
Same institution · by research overlap
- William John McBride$1,257,246
- William A. Wegener$2,714,853
Others in their field
Top investigators on “Pre-Clinical”
- Leonard Freedman · Leidos Biomedical Research, Inc.$264,541,531
- Dennis R. Burton · Scripps Research Institute$257,157,696
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barton F Haynes · Duke University$186,001,832
- David Heimbrook · Leidos Biomedical Research, Inc.$151,740,590
- Reisa A. Sperling · Banner Health$137,047,788
Research focus
Pre-ClinicalMouse ModelClinical TrialsSafetyTumorSiteSerumPropertyStructureSmall Business Innovation Research GrantDrug KineticsBaseTumor XenograftDesignLungAffinityBinding (Molecular Function)LeadPreclinical StudyToxic EffectBehaviorDockingDoseCarcinoembryonic Antigen
Grant awards (5)
Use of milatuzumab in modulating graft vs. host disease$191,143
R41 · FY2011 · AI · contact PI
Dock and Lock: Novel Protein Engineering$366,809
R44 · FY2009 · CA · contact PI
Dock and Lock: Novel Protein Engineering$520,817
R44 · FY2008 · CA · contact PI
Novel RNase-based Immunotoxin for CD74-positive B-cell Malignancies$134,285
R43 · FY2007 · CA · contact PI
Dock and Lock: novel protein engineering$134,285
R43 · FY2006 · CA · contact PI